์ํ๋ฆฐ ๋ํธ๋ฅจ
์ํ๋ฆฐ์ ์ฟ ๋ง๋ฆฐ๊ณ ํญ์๊ณ ์ ๋ก, ์ฃผ๋ก ๊ณ ์์ด, ๊ฐ, ๋ง์ ํ์ ์ฑ ์งํ์ ์ฅ๊ธฐ ์น๋ฃ ๋ฐ ์๋ฐฉ์ ์ฌ์ฉ๋ฉ๋๋ค. ์น๋ฃ ์ง์๊ฐ ์ข๊ณ ์น๋ช ์ ์ธ ์ถํ ์ํ์ด ์์ผ๋ฉฐ ๋น๋ฒํ๊ณ ๋น์ฉ์ด ๋ง์ด ๋๋ ์๊ณ ๋ชจ๋ํฐ๋ง์ด ํ์ํ๊ธฐ ๋๋ฌธ์ ์์ํ์์์ ์ฌ์ฉ์ ๋ค์ ๋ ผ๋์ด ์์ผ๋ฉฐ, ๋ค๋ฅธ ํญ์๊ณ ์ ๋ฅผ ์ฌ์ฉํ ์ ์๋ ํน์ ๊ฒฝ์ฐ์ ์ฃผ๋ก ์ฌ์ฉ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Warfarin acts as an indirect anticoagulant by antagonizing Vitamin K. * It competitively inhibits the enzyme **Vitamin K epoxide reductase (VKORC1)**. * This inhibition prevents the conversion of inactive Vitamin K epoxide back into its active form (Vitamin K hydroquinone). * Active Vitamin K is an essential cofactor for the ฮณ-carboxylation (activation) of **coagulation factors II, VII, IX, and X**, as well as the endogenous anticoagulant proteins C and S. * **Pathway:** VKORC1 inhibition โ Depletion of active Vitamin K โ Production of inactive, undercarboxylated clotting factors (PIVKA) โ Prolonged clotting times and anticoagulation.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Adjunctive maintenance therapy for venous thrombosis with or without pulmonary thromboembolism (PTE) ยท 0.5 mg (total dose per cat) ยท PO ยท once daily ยท Initially, then adjusted to achieve a PT prolongation of 1.25 to 1.5 times the pretreatment value.
- Maintenance therapy for feline arterial thromboembolism ยท 0.06 to 0.09 mg/kg/day ยท PO ยท once daily ยท Heparinization is recommended during the first 5 to 7 days that warfarin is administered.
- Long-term thromboprophylaxis ยท 0.06-0.09 mg/kg per day ยท PO ยท once daily ยท Initially. Tablets should be crushed and mixed well due to unequal drug distribution. Overlap heparin and warfarin therapy by at least 4-5 days.
- Adjunctive therapy of thromboembolism ยท 0.25-0.5 mg (total dose) per cat ยท PO ยท once daily ยท Initially. Adjust dosage to prolong PT to twice normal value, or INR to be between 2-3. Overlap therapy with heparin.
- Cardiogenic arterial thromboembolism ยท 0.25-0.5 mg total dose per cat ยท PO ยท q24h ยท Heparin (150-250 Units/kg SC q8h) should be administered concurrently during the first 4-6 days. Target PT range is 1.3-1.6 times baseline, or INR 2.0-3.0.
- Adjunctive treatment of laminitis ยท 0.0198 mg/kg ยท PO ยท once daily ยท Monitor OSPT (one-step prothrombin time) until prolonged 2-4 seconds beyond baseline.
- Anticoagulant ยท Initially, 0.018 mg/kg PO once daily and increase dose by 20% every day until baseline PT is doubled. Final dose rates may be from 0.012 mg/kg to 0.57 mg/kg daily. ยท PO ยท once daily ยท ARCI UCGFS Class 5 Drug.
- Adjunctive maintenance therapy for venous thrombosis with or without pulmonary thromboembolism (PTE) ยท 0.22 mg/kg ยท PO ยท q12h ยท Initially, then adjusted to achieve a PT prolongation of 1.25 to 1.5 times the pretreatment value.
- Adjunctive therapy of thromboemboli ยท 0.22 mg/kg ยท PO ยท q12h ยท Target dosage to prolong PT by 1.25-1.5 times the pretreatment value.
- Prophylactic use in patients with glomerular disease and severe proteinuria ยท 0.22 mg/kg ยท PO ยท once daily ยท Initially. Monitor PT and adjust dose so that PT is maintained at 1.5 times normal.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Preexistent hemorrhagic tendencies or diseases
- Patients undergoing or contemplating eye or CNS surgery
- Major regional lumbar block anesthesia
- Surgery of large, open surfaces
- Active bleeding from the GI, respiratory, or GU tract
- Aneurysm
- Acute nephritis
- Cerebrovascular hemorrhage
- Blood dyscrasias
- Uncontrolled or malignant hypertension
- Hepatic insufficiency
- Pericardial effusion
- Pregnancy (Teratogenic - FDA Category X / Papich Class D)
- Visceral carcinomas
์ด์๋ฐ์
- Dose-related hemorrhage (primary adverse effect)
- Anemia
- Thrombocytopenia
- Weakness
- Hematomas and ecchymoses
- Epistaxis (nosebleeds)
- Hematemesis (vomiting blood)
- Hematuria (blood in urine)
- Melena (dark, tarry stools)
- Hematochezia (fresh blood in stools)
- Hemarthrosis (bleeding into joints)
- Hemothorax
- Intracranial hemorrhage
- Pericardial hemorrhage
- Death
์ฝ๋ฌผ ์ํธ์์ฉ
- Acetaminophen, NSAIDs, Salicylates ยท May increase anticoagulant response (via protein displacement or platelet inhibition); increases bleeding risk.
- Fluoroquinolones, Macrolides (Azithromycin, Erythromycin), Chloramphenicol, Sulfonamides, Co-trimoxazole ยท May increase anticoagulant response (often via inhibition of hepatic metabolism).
- Cimetidine, Cisapride, Fluoxetine, Metronidazole, Sertraline ยท May increase anticoagulant response.
- Amiodarone, Allopurinol, Danazol, Diazoxide, Ethacrynic acid, Pentoxifylline, Propylthiouracil, Quinidine, Zafirlukast ยท May increase anticoagulant response.
- Anabolic Steroids, Thyroid Medications ยท May increase anticoagulant response.
- Heparin ยท Increases anticoagulant response; often used concurrently during the initial overlap phase but requires careful monitoring.
- Barbiturates (e.g., Phenobarbital), Rifampin, Griseofulvin ยท May decrease anticoagulant response (via induction of hepatic metabolizing enzymes).
- Corticosteroids, Estrogens, Mercaptopurine, Spironolactone, Sucralfate ยท May decrease anticoagulant response.
- Vitamin K ยท Directly antagonizes warfarin, decreasing its anticoagulant response (used as an antidote for overdose).
๋ชจ๋ํฐ๋ง
- Prothrombin Time (PT) - Target usually 1.25 to 1.5x (or up to 2x) normal depending on protocol
- International Normalized Ratio (INR) - Target usually 2.0 to 3.0 (Note: not fully validated for veterinary patients)
- PIVKA (Proteins Induced by Vitamin K Antagonists) - May be more sensitive than PT
- Platelet counts and hematocrit (PCV)
- Occult blood in stool and urine
- Physical observations for bleeding (mucous membranes, bruising, epistaxis)
- Clinical efficacy (resolution/prevention of thromboembolism)
๊ณผ์ฉ๋
Acute overdosages of warfarin may result in life-threatening hemorrhage. * **Toxic Doses:** In dogs and cats, single doses of 5-50 mg/kg have been associated with toxicity. Cumulative toxic doses are reported as 1-5 mg/kg for 5-15 days in dogs, and 1 mg/kg for 7 days in cats. * **Lag Time:** A lag time of 2-5 days may occur before clinical signs of toxicity manifest. Animals must be monitored closely during this period. * **Treatment:** If detected early, prevent absorption from the gut using standard decontamination protocols (emesis, activated charcoal). If clinical signs of bleeding are noted, treat with blood products (plasma/whole blood to replace active clotting factors) and **Vitamin K1 (phytonadione)**.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.